GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » Cyclically Adjusted FCF per Share

BioRestorative Therapies (FRA:9OF) Cyclically Adjusted FCF per Share : €-2,198.60 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioRestorative Therapies's adjusted free cash flow per share for the three months ended in Jun. 2024 was €-0.213. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2,198.60 for the trailing ten years ended in Jun. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 26.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioRestorative Therapies was 26.80% per year. The lowest was 26.80% per year. And the median was 26.80% per year.

As of today (2024-09-22), BioRestorative Therapies's current stock price is €1.37. BioRestorative Therapies's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was €-2,198.60. BioRestorative Therapies's Cyclically Adjusted Price-to-FCF of today is .


BioRestorative Therapies Cyclically Adjusted FCF per Share Historical Data

The historical data trend for BioRestorative Therapies's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Cyclically Adjusted FCF per Share Chart

BioRestorative Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -5,788.94 -4,544.68 -3,262.53

BioRestorative Therapies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,741.31 -3,318.02 -3,262.53 -2,892.51 -2,198.60

Competitive Comparison of BioRestorative Therapies's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, BioRestorative Therapies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Cyclically Adjusted Price-to-FCF falls into.



BioRestorative Therapies Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioRestorative Therapies's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.213/132.5538*132.5538
=-0.213

Current CPI (Jun. 2024) = 132.5538.

BioRestorative Therapies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -2,087.097 100.428 -2,754.742
201412 -1,317.949 99.070 -1,763.396
201503 -1,852.381 99.621 -2,464.740
201506 -775.000 100.684 -1,020.314
201509 -706.000 100.392 -932.180
201512 -1,012.000 99.792 -1,344.235
201603 -1,624.000 100.470 -2,142.595
201606 -960.000 101.688 -1,251.392
201609 -1,103.000 101.861 -1,435.356
201612 -1,014.000 101.863 -1,319.517
201703 -1,140.000 102.862 -1,469.066
201706 -682.000 103.349 -874.722
201709 -427.000 104.136 -543.527
201712 -574.500 104.011 -732.154
201803 -469.500 105.290 -591.075
201806 -445.000 106.317 -554.818
201809 -580.000 106.507 -721.844
201812 -455.000 105.998 -568.992
201903 -438.000 107.251 -541.336
201906 -250.800 108.070 -307.621
201909 -259.000 108.329 -316.917
201912 -85.789 108.420 -104.885
202003 -1.018 108.902 -1.239
202006 -0.935 108.767 -1.139
202009 -1.113 109.815 -1.343
202012 -0.656 109.897 -0.791
202103 -0.861 111.754 -1.021
202106 -0.736 114.631 -0.851
202109 -0.614 115.734 -0.703
202112 -0.288 117.630 -0.325
202203 -0.439 121.301 -0.480
202206 -0.361 125.017 -0.383
202209 -0.396 125.227 -0.419
202212 -0.473 125.222 -0.501
202303 -0.613 127.348 -0.638
202306 -0.312 128.729 -0.321
202309 -0.206 129.860 -0.210
202312 -0.361 129.419 -0.370
202403 -0.320 131.776 -0.322
202406 -0.213 132.554 -0.213

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


BioRestorative Therapies  (FRA:9OF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioRestorative Therapies Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies Headlines

No Headlines